Furtado, Remo H.M.
Hospital Israelita Albert Einstein · Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · Instituto do Coração - HCFMUSP
5 papers on CoChatORCID 0000-0003-4639-1003
Most cited papers
- Verified
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 2,845
- Verified
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 781
- Verified
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus
Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 557
- Verified · note
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
Zelniker, T. A., Bonaca, M. P., Furtado, R. H. M., Mosenzon, O., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2020) · Circulation
Diabetes Treatment and ManagementAtrial Fibrillation Management and Outcomes
Cited by 459
- Verified
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial
Kosiborod, M. N., Esterline, R., Furtado, R. H. M., Oscarsson, J., Gasparyan, S. B., Koch, G. G., Martinez, F., Mukhtar, O., Verma, S., Chopra, V., et al. (2021) · The Lancet Diabetes & Endocrinology
COVID-19 Clinical Research StudiesDiabetes Treatment and Management
Cited by 243
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free